Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide and Etoposide in Advanced Head and Neck Squamous Cell Carcinoma
NCT07361133Phase 2Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, etoposide in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
cyclophosphamideetoposide
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07361133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361133.